Pediatric participants will be enrolled as follows:~Pediatric participants ≥ 28 days to < 18 years old:~Cohort 1: ≥ 12 years to < 18 years and weight ≥ 40 kg~Cohort 2: ≥ 28 days to < 18 years and weight ≥ 20 kg to < 40 kg~Cohort 3: ≥ 28 days to < 18 years and weight ≥ 12 kg to < 20 kg~Cohort 4: ≥ 28 days to < 18 years and weight ≥ 3 kg to < 12 kg~Cohort 8: < 12 years and weight ≥ 40 kg~Term neonatal participants 0 days to < 28 days old:~Cohort 5: ≥ 14 days to < 28 days of age, gestational age > 37 weeks and weight at screening ≥ 2.5 kg~Cohort 6: 0 days to < 14 days of age, gestational age > 37 weeks and birth weight ≥ 2.5 kg~Preterm neonates and infants 0 days to < 56 days old:~Cohort 7: 0 days to < 56 days of age, gestational age ≤ 37 weeks and birth weight ≥ 1.5 kg
The goals of this clinical study are to learn more about the study drug, remdesivir, and how safe it is in participants 18 years old and younger with coronavirus disease 2019 (COVID-19).